BMS-986446 subcutaneous bioavailability in healthy volunteers

Phase 1, randomised, open-label trial of nivolumab (subcutaneous) in tauopathy (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Geometric Mean Ratio of Maximum Observed Serum Concentration of BMS-986446 Administered IV versus SC at 85 days, Geometric Mean Ratio of Area Under the Serum Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration of BMS-986446 Administered IV versus SC at 85 days and 2 more. Started May 2025; status: completed.